Details
Ganciclovir-Pharmex Indications
Ganciclovir-Pharmex is indicated in adults and adolescents ≥ 12 years of age for:
treatment of cytomegalovirus (CMV) infection in immunocompromised patients;
prevention of CMV infection through preventive therapy in patients with drug-induced immunosuppression (for example, after organ transplantation or cancer chemotherapy).
Ganciclovir-Pharmex is also indicated for children from birth to prevent CMV infection by universal prophylaxis in patients with drug-induced immunosuppression (for example, after organ transplantation or cancer chemotherapy).
Contraindications Dosage and administration
Hypersensitivity to ganciclovir, valganciclovir or to another component of the drug.
Lactation.
Dosage and administration
Caution: Ganciclovir should be administered by intravenous infusion over 1 hour at a concentration not exceeding 10 mg / ml. Do not administer by rapid or bolus injection, as the toxicity of ganciclovir may increase due to excessive plasma levels.
It should not be administered by intramuscular or subcutaneous injection, as this can lead to severe tissue irritation due to the high pH (~ 11) of the ganciclovir solution.
Do not exceed the recommended dose, frequency or rate of infusion.
Ganciclovir-Pharmex is a lyophilisate (powder) for the preparation of a solution for infusion. After reconstitution, Ganciclovir-Pharmex is a colorless to light yellow solution, with practically no visible particles.
The infusion should be in a vein with adequate blood flow, preferably through a plastic cannula.
